Cogent Biosciences, Inc. Share-based Payment Arrangement, Accelerated Cost
Cogent Biosciences, Inc. (COGT) reported Share-based Payment Arrangement, Accelerated Cost of $700.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2025-11-07
- Cogent Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-12-31 was $400.00K.
- Cogent Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-09-30 was $300.00K.
- Cogent Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-06-30 was $300.00K.
- Cogent Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2024-03-31 was $0.00.
- Cogent Biosciences, Inc. share-based payment arrangement, accelerated cost for fiscal 2024 was $1.00M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $700.00K 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $700.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.00M 10-K · filed 2025-02-25 |
| 2024-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $600.00K derived: sum of 2 quarters · filed 2024-11-12 | $600.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $300.00K 10-Q · filed 2024-08-06 | $300.00K 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |